ライフサイエンスコーパス: poliomyelitis

1 ulation, still struggling for eradication of poliomyelitis.

2 P assembly may be shared features of SMA and poliomyelitis.

3 ing the risk of vaccine-associated paralytic poliomyelitis.

4 s, encephalitis, and acute flaccid paralysis/poliomyelitis.

5 part of the worldwide campaign to eradicate poliomyelitis.

6 , pancreatitis, acute flaccid paralysis, and poliomyelitis.

7 causes a paralytic condition consistent with poliomyelitis.

8 t with a viral encephalomyelitis, similar to poliomyelitis.

9 ing intramuscular injections and provocation poliomyelitis.

10 al oral human infection leading to paralytic poliomyelitis.

11 by the age distribution of the children with poliomyelitis.

12 valuated for induced immunity against type 3 poliomyelitis.

13 that are still struggling for eradication of poliomyelitis.

14 an Health Organization as cases of suspected poliomyelitis.

15 rus vaccines (OPVs) are the leading cause of poliomyelitis.

16 ral immunity and has been key to controlling poliomyelitis.

17 imates of the efficacy of these OPVs against poliomyelitis.

18 inate vaccine-associated and vaccine-derived poliomyelitis.

19 otection from paralysis in a murine model of poliomyelitis.

20 elerate eradication and prevent outbreaks of poliomyelitis.

21 ous diseases including smallpox, measles and poliomyelitis.

22 alth Assembly resolved to globally eradicate poliomyelitis.

23 on of safety in primate models for paralytic poliomyelitis.

24 and associated increases in the incidence of poliomyelitis.

25 revert to neurovirulence and cause paralytic poliomyelitis.

26 cases (95% UI, 0-26 300 cases) of paralytic poliomyelitis, 10.3 million hospitalizations (95% UI, 9.

27 cts of individuals with laboratory-confirmed poliomyelitis, 27 (12.7%) of 213 and 29 (13.9%) of 209 h

28 31, 2011, there were 883 cases of serotype 1 poliomyelitis (710 in Pakistan and 173 in Afghanistan) a

29 s is poliovirus (PV), the causative agent of poliomyelitis, a condition characterized by acute flacci

30 Poliovirus (PV) is the causative agent of poliomyelitis, a crippling human disease known since ant

31 e and cause paralytic disease (age-dependent poliomyelitis [ADPM]).

32 eptor (PVR) gene (TgPVR mice), which develop poliomyelitis after intracerebral inoculation, are not s

33 637 days without developing any symptoms of poliomyelitis, after which excretion appeared to have ce

34 rted number of doses received by people with poliomyelitis and by matched controls as identified in N

35 Health (MOH), national surveillance data for poliomyelitis and charts of cases at the national rehabi

36 myelitis due to vaccine-associated paralytic poliomyelitis and circulating vaccine-derived poliovirus

37 the CNS, with augmented progression of acute poliomyelitis and dorsal root ganglionic inflammation ra

38 for paralytic polio in an animal system for poliomyelitis and have determined the pathogenic mechani

39 Recent American successes against poliomyelitis and measles have been attributed to repeat

40 quantitatively assessed the epidemiology of poliomyelitis and programme performance and considered t

41 case was defined as a diagnosis of paralytic poliomyelitis and residual paralysis at 60 days in a pat

42 ent oral poliovirus vaccine (OPV) to prevent poliomyelitis and the season when children were vaccinat

43 standard dose, 120 to Chumakov Institute of Poliomyelitis and Viral Encephalitides fractional dose,

44 ractional dose, 120 to Chumakov Institute of Poliomyelitis and Viral Encephalitides standard dose, 12

45 0% (-4.24 to 3.13) for Chumakov Institute of Poliomyelitis and Viral Encephalitides, 1.82% (-2.75 to

46 were collected from children with confirmed poliomyelitis and were used to assess correlates of vacc

47 uropathogenic potential in animal models for poliomyelitis and, at a very low rate, they can cause po

48 , meningitis, septicemia, herpes zoster, and poliomyelitis), and inflammatory (glomerulonephritis, ne

49 s (95% UI, 4 cases to 21.5 million cases) of poliomyelitis, and 197 cases of diphtheria.

50 es were estimated cases of measles, rubella, poliomyelitis, and diphtheria in the US.

51 er's first surveillance systems for malaria, poliomyelitis, and influenza.

52 gic principles for the global eradication of poliomyelitis are as follows: Poliovirus causes acute, n

53 because oral polio vaccine can rarely cause poliomyelitis as it mutates and may fail to provide adeq

54 From 1988 to 1993, 30 cases of poliomyelitis associated with poliovirus type 2 were fou

55 surveillance data recording the presence of poliomyelitis associated with wild-type 1 poliovirus in

56 A, Japanese encephalitis, meningitis A, and poliomyelitis) based on data availability and their subs

57 ely correlated with the probability of VDPV2 poliomyelitis being reported in a district.

58 pinal cord anterior horn cells; thus, severe poliomyelitis, but not acute encephalitis, was observed

59 Despite substantial efforts to eradicate poliomyelitis by administering oral poliovirus vaccine t

60 e individually matched with children who had poliomyelitis by age, sex, and residence.

61 o the PV receptor (PVR) and causes paralytic poliomyelitis by replicating within motor neurons of the

62 be chronically infected with poliovirus, and poliomyelitis can develop despite treatment with intrave

63 Sabin vaccine strains used in prevention of poliomyelitis carry such mutations in their IRES element

64 We estimate from the poliomyelitis case count and the paralytic case-to-infec

65 The last imported poliomyelitis case occurred in 1993 and the last case of

66 rgency protection of contacts of a paralytic poliomyelitis case.

67 io, Pakistan bears the highest proportion of poliomyelitis cases among the 3 endemic countries includ

68 us and reasons for undervaccination among 66 poliomyelitis cases and 130 age- and neighborhood-matche

69 After 25 years without poliomyelitis cases caused by circulating wild polioviru

70 d lead to roughly 200 000 expected paralytic poliomyelitis cases every year in low-income countries,

71 Fatal poliomyelitis cases gave laboratory evidence of previous

72 to detect WPV circulation in the absence of poliomyelitis cases in many communities.

73 demicity, 1900-1950, the age distribution of poliomyelitis cases increased gradually.

74 May 2016 and 29 September 2023, 3,120 cVDPV2 poliomyelitis cases were reported across 75 outbreaks in

75 , which is consistent with recent absence of poliomyelitis cases; whereas seroprevalence against type

76 An epidemic of poliomyelitis caused by poliovirus type 1 occurred in Th

77 hed case-control pairs of confirmed cases of poliomyelitis caused by type 1 wild poliovirus and cases

78 Available literature on outbreaks of poliomyelitis caused by wild polioviruses between 1996 a

79 The global eradication of poliomyelitis caused by wild-type virus is likely to be

80 for the Certification of the Eradication of Poliomyelitis certified the eradication of type 2 poliov

81 This phenomenon, labeled "provocation poliomyelitis," continues to cause numerous cases of chi

82 irus vaccines led to a stepwise reduction in poliomyelitis, culminating in the unpredicted eliminatio

83 cases of circulating vaccine-derived type 2 poliomyelitis (cVDPV2) were reported globally and supple

84 The odds of observing poliomyelitis decreased with improved routine or supplem

85 one of the compounds in an in vivo model of poliomyelitis demonstrated partial protection from the o

86 st three times more effective against type 1 poliomyelitis disease than is trivalent vaccine.

87 Five cases of poliomyelitis due to type 2 or 3 recombinant vaccine-der

88 accine (OPV) results in an ongoing burden of poliomyelitis due to vaccine-associated paralytic poliom

89 The last patient with poliomyelitis due to wild poliovirus in the Americas had

90 igated; none has been confirmed as paralytic poliomyelitis due to wild poliovirus.

91 den acute respiratory syndrome (SARS), H1N1, Poliomyelitis, Ebola, Zika, Nipah, Middle Eastern respir

92 veral previous fearsome epidemics-during the poliomyelitis epidemic in the 1930s-1950s, and again dur

93 stigations included the study of the Buffalo poliomyelitis epidemic of 1912, by Wade Hampton Frost, w

94 sion for the Certification of Eradication of Poliomyelitis Eradication (ICCPE) was established by the

95 national Commission for the Certification of Poliomyelitis Eradication declared the Americas to be po

96 years are a critical component of the global poliomyelitis eradication effort.

97 ay become relevant during the final phase of poliomyelitis eradication in populations with predominan

98 Regional Commission for the Certification of Poliomyelitis Eradication in the Western Pacific certifi

99 resolution on intensification of the Global Poliomyelitis Eradication Initiative (GPEI), the Nigeria

100 The completion of poliomyelitis eradication is a global emergency for publ

101 veloping "endgame" strategies for the Global Poliomyelitis Eradication Program.

102 ental surveillance (ES) of poliovirus in the poliomyelitis eradication strategic plan as an activity

103 ed data on 2296 cases of GBS reported to the Poliomyelitis Eradication Surveillance System of the Pan

104 The "endgame" for worldwide poliomyelitis eradication will entail eventual cessation

105 fficient vaccination have hindered worldwide poliomyelitis eradication, as they are vulnerable to spo

106 Focusing on the large costs for poliomyelitis eradication, without assessing the even la

107 of combined diphtheria-tetanus-pertussis and poliomyelitis expanded vaccines with the first of three

108 duced population immunity against serotype-2 poliomyelitis for 1 January 2004-30 June 2015 and produc

109 guarding neurons against axonal blebbing and poliomyelitis from murine betacoronavirus-induced neuroi

110 olioviruses and vaccine-associated paralytic poliomyelitis from Sabin oral poliovirus vaccines (OPVs)

111 minate vaccine-associated or vaccine-derived poliomyelitis from serotype 2 poliovirus.

112 erica as part of the initiative to eradicate poliomyelitis from the Western Hemisphere.

113 lls are critical for controlling acute-stage poliomyelitis (gray matter inflammation), chronic axonal

114 cases of paralysis often in countries where poliomyelitis had not occurred for many years.

115 anus toxoids-acellular pertussis-inactivated poliomyelitis-Haemophilus influenza type b-hepatitis B c

116 From smallpox to poliomyelitis, halting contagion transmission through si

117 Poliomyelitis has appeared in epidemic form, become ende

118 Although poliomyelitis has been mostly eradicated worldwide, larg

119 The number of cases of paralytic poliomyelitis has declined in Nigeria since the introduc

120 This investigation confirms that poliomyelitis has remained endemic in Angola since indep

121 Moreover, several outbreaks of poliomyelitis have been shown to be caused by viruses de

122 elae, congenital rubella syndrome, paralytic poliomyelitis, hospitalization, and death) and the proba

123 likely to protect >80% of recipients against poliomyelitis if poliovirus reemerges after withdrawal o

124 ation, having contributed to 73% of reported poliomyelitis in 2015 and 54% in 2016.

125 to detect poliovirus infections or paralytic poliomyelitis in Amish communities in Minnesota, neighbo

126 on is evidenced by the documented absence of poliomyelitis in an increasing number of countries and t

127 Control of poliomyelitis in Angola is essential to expand the polio

128 of HEV-C may share PV's potential to elicit poliomyelitis in humans.

129 e the key factors sustaining transmission of poliomyelitis in Nigeria and to calculate clinical effic

130 ine immunization was a major risk factor for poliomyelitis in Pakistan.

131 iated with fatal outcomes among persons with poliomyelitis in Pointe Noire.

132 e likelihood of vaccine-associated paralytic poliomyelitis in recipients of live attenuated polioviru

133 The last case of poliomyelitis in the United States due to indigenously a

134 The increasing incidence of poliomyelitis in these countries during 2010-11 led the

135 itis and, at a very low rate, they can cause poliomyelitis in vaccine recipients.

136 the impact of nOPV2 and mOPV2 SIAs on cVDPV2 poliomyelitis incidence and prevalence in environmental

137 Six-month forecasts of poliomyelitis incidence by district for 2013-2016 showed

138 rns are important determinants of historical poliomyelitis incidence in Pakistan; however, movement d

139 Reasons for continued high poliomyelitis incidence include failure to vaccinate, va

140 act (adjusted relative risk [aRR] for cVDPV2 poliomyelitis incidence per nOPV2 SIA, 0.505; 95% confid

141 (radiation) was a significant determinant of poliomyelitis incidence, it did not improve the predicti

142 erion [AIC]) to produce 6-month forecasts of poliomyelitis incidence.

143 lenges to the final eradication of paralytic poliomyelitis include the continued transmission of wild

144 erve as a possible determinant of widespread poliomyelitis infection in Pakistan and further emphasiz

145 In contrast to measles, smallpox and poliomyelitis, influenza is caused by viruses that under

146 Poliomyelitis is a highly infectious disease caused by P

147 Poliomyelitis is a highly infectious disease caused by p

148 om a child with vaccine-associated paralytic poliomyelitis is described.

149 recapitulates human poliovirus infection and poliomyelitis, it can be used to study polio pathogenesi

150 recapitulates human poliovirus infection and poliomyelitis, it can be used to study polio pathogenesi

151 t patients with vaccine-associated paralytic poliomyelitis (iVAPP), cases reported in the United Stat

152 The Pan American Regional Poliomyelitis Laboratory Network, developed to support t

153 foot, and mouth disease, aseptic meningitis, poliomyelitis-like acute flaccid paralysis, brainstem en

154 ad meningitis, 8 had encephalitis, and 3 had poliomyelitis-like acute flaccid paralysis.

155 as WNV-infected humans can also experience a poliomyelitis-like disease where motor neurons are damag

156 t ever outbreak of West Nile encephalitis; a poliomyelitis-like flaccid paralysis due to West Nile vi

157 rological diseases, such as encephalitis and poliomyelitis-like paralysis.

158 of acute flaccid myelitis (AFM), which is a poliomyelitis-like paralytic illness.

159 outbreaks of acute flaccid myelitis (AFM), a poliomyelitis-like spinal cord syndrome that can result

160 long-term outcome, although an irreversible poliomyelitis-like syndrome may result.

161 The pathogenic mechanism of provocation poliomyelitis may differ from that of polio acquired in

162 04) data for diphtheria, pertussis, tetanus, poliomyelitis, measles, mumps, rubella (including congen

163 In recent years, outbreaks of dengue, poliomyelitis, measles, pertussis, meningococcal disease

164 les, mumps, pertussis, pneumococcal disease, poliomyelitis, meningococcal disease, rubella, tetanus,

165 ant and widespread human diseases, including poliomyelitis, myocarditis, acute flaccid myelitis and t

166 r 1991 and March 1992, 37 cases of paralytic poliomyelitis occurred in Jordan, where none had been re

167 An outbreak of paralytic poliomyelitis occurred in the Dominican Republic (13 con

168 nsible for severe paralytic diseases such as poliomyelitis or acute flaccid myelitis.

169 ination against diphtheria-tetanus-pertussis-poliomyelitis (OR = 1.5) and was not statistically signi

170 Since 2005, a large poliomyelitis outbreak associated with type 2 circulatin

171 A poliomyelitis outbreak caused by type 1 circulating vacc

172 A paralytic poliomyelitis outbreak occurred in Namibia in 2006, almo

173 sights into the dynamics of future potential poliomyelitis outbreaks and in this way serve as a usefu

174 ulating vaccine-derived PVs that have caused poliomyelitis outbreaks in different parts of the world.

175 rd eradication of poliomyelitis, the risk of poliomyelitis outbreaks resulting from virus importation

176 cine-derived poliovirus (VDPV), which causes poliomyelitis outbreaks similar to those caused by wild

177 vaccine-derived poliovirus (VDPV) and cause poliomyelitis outbreaks.

178 ssed their association with the incidence of poliomyelitis over time in seven regions of Afghanistan

179 olates obtained over a 337-day period from a poliomyelitis patient from Taiwan with common variable i

180 olates obtained over a 189-day period from a poliomyelitis patient with common variable immunodeficie

181 e-derived isolates from an immunocompromised poliomyelitis patient, the contacts, and the local sewag

182 Poliomyelitis patients admitted to Angola's main pediatr

183 recombinant polioviruses were isolated from poliomyelitis patients in China from 1991 to 1993.

184 cination, including the diphtheria, tetanus, poliomyelitis, pertussis, or Haemophilus influenzae (DTP

185 phtheria, tetanus, and pertussis (DTP3); and poliomyelitis (polio3)--as dependent variables.

186 s from cases of vaccine-associated paralytic poliomyelitis related to the CHAT vaccine revealed genet

187 Poliomyelitis remains a global threat despite availabili

188 contact with 2761 individuals with suspected poliomyelitis reported during the period 2003-2008.

189 ed a significant decline in the incidence of poliomyelitis, reported in 58 districts in 2019 and just

190 ouse hepatocytes and Primary Liver Carcinoma/Poliomyelitis Research Foundation/5- ASBT cells.

191 rus has caused meningitis, encephalitis, and poliomyelitis, resulting in significant morbidity and mo

192 offs among different strategies for managing poliomyelitis risks after they succeed with polio eradic

193 e the success of current vaccination against poliomyelitis, safe, cheap and effective vaccines remain

194 tan and 173 in Afghanistan) and 272 cases of poliomyelitis serotype 3 (216 in Pakistan and 56 in Afgh

195 lateral sclerosis or West Nile Virus-induced poliomyelitis, suggesting a common tissue injury pathway

196 e substantial progress toward eradication of poliomyelitis, the risk of poliomyelitis outbreaks resul

197 persons (iVDPV) presents a personal risk of poliomyelitis to the patient as well as a programmatic r

198 ous population immunity continued to support poliomyelitis transmission in Nigeria at the end of 2012

199 classical multivalent vaccines, inactivated poliomyelitis vaccine (IPOL), RotaTeq, and Gardasil-9, d

200 -to introduce at least 1 dose of inactivated poliomyelitis vaccine (IPV); withdraw oral poliomyelitis

201 d poliomyelitis vaccine (IPV); withdraw oral poliomyelitis vaccine (OPV), starting with the type 2 co

202 oradic cases of vaccine-associated paralytic poliomyelitis (VAPP) and the emergence of genetically di

203 f patients with vaccine-associated paralytic poliomyelitis (VAPP) in Hungary during 1961-1981 were re

204 e rare cases of vaccine-associated paralytic poliomyelitis (VAPP) in OPV recipients and their close c

205 Vaccine-associated paralytic poliomyelitis (VAPP) is a rare adverse event associated

206 e of 9 cases of vaccine-associated paralytic poliomyelitis (VAPP) were confirmed each year from 1961

207 development of vaccine-associated paralytic poliomyelitis (VAPP).

208 onjunction with vaccine-associated paralytic poliomyelitis (VAPP).

209 ons, leading to vaccine-associated paralytic poliomyelitis (VAPP).

210 f a dose of trivalent OPV against serotype 1 poliomyelitis was 12.5% (95% CI 5.6-18.8) compared with

211 poliovirus vaccine against type 3 paralytic poliomyelitis was 18% (95% CI, 9 to 26).

212 The vaccination history of children with poliomyelitis was compared with that of children with ac

213 Immunity against serotype-2 poliomyelitis was forecasted to improve in April 2016 co

214 The ensuing outbreak of poliomyelitis was investigated: Patients with poliomyeli

215 poliovirus vaccine against type 1 paralytic poliomyelitis were 67% (95% confidence interval [CI], 39

216 No cases of vaccine-associated paralytic poliomyelitis were detected.

217 oliomyelitis was investigated: Patients with poliomyelitis were evaluated, the extent of poliovirus c

218 Children with poliomyelitis were more likely to have received doses in

219 rom 1990 through 1999, 61 cases of paralytic poliomyelitis were reported; 59 (97%) of these were VAPP

220 PV cause poliomyelitis, whereas CAV21 shares a receptor and a pro

221 s would lead to a sustainable eradication of poliomyelitis while simultaneously promoting immunisatio

222 therefore be used in eradicating serotype 1 poliomyelitis whilst minimising the risks of serotype 3

223 e vaccinated, 46 children 1-7 years old with poliomyelitis who had received three card-documented dos

224 During 1976-1995, 48 outbreaks of paralytic poliomyelitis with a cumulative total of approximately 1

225 on and presents a disease pattern resembling poliomyelitis with seasonal epidemics that include cases

226 In 2010, a large outbreak of poliomyelitis with unusual 47% lethality occurred in Poi

227 transmission of wild polioviruses (WPVs) and poliomyelitis, with the last case of WPV type 2 in the w

228 viduals was associated with the incidence of poliomyelitis, with the radiation model of movement prov

229 ic phenotype in a transgenic mouse model for poliomyelitis without diminishing the growth properties

230 A mean of 86 cases of poliomyelitis/year were reported in Angola during 1989-1